These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 38548262)
41. The past, present and future of tuberculosis treatment. Bi K; Cao D; Ding C; Lu S; Lu H; Zhang G; Zhang W; Li L; Xu K; Li L; Zhang Y Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):657-668. PubMed ID: 36915970 [TBL] [Abstract][Full Text] [Related]
42. Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches. Kumar A; Karkara BB; Panda G Chem Biol Drug Des; 2021 Nov; 98(5):787-827. PubMed ID: 34397161 [TBL] [Abstract][Full Text] [Related]
43. Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis. Rollo RF; Mori G; Hill TA; Hillemann D; Niemann S; Homolka S; Fairlie DP; Blumenthal A Microbiol Spectr; 2023 Aug; 11(4):e0046523. PubMed ID: 37289062 [TBL] [Abstract][Full Text] [Related]
44. Association between antiretroviral therapy and antitubercular drug resistance in TB treatment outcome among Kazakh TB/HIV co-infected patients. Mishkin K; Alaei K; Alikeyeva E; Paynter C; Aringazina A; Alaei A J Glob Antimicrob Resist; 2018 Sep; 14():104-108. PubMed ID: 29496619 [TBL] [Abstract][Full Text] [Related]
45. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease. Palucci I; Delogu G Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143 [TBL] [Abstract][Full Text] [Related]
46. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
47. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design. Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290 [TBL] [Abstract][Full Text] [Related]
48. Development of new drug-regimens against multidrug-resistant tuberculosis. Vasava MS; Nair SG; Rathwa SK; Patel DB; Patel HD Indian J Tuberc; 2019 Jan; 66(1):12-19. PubMed ID: 30797268 [TBL] [Abstract][Full Text] [Related]
49. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Heyckendorf J; Olaru ID; Ruhwald M; Lange C Am J Respir Crit Care Med; 2014 Aug; 190(4):374-83. PubMed ID: 24941306 [TBL] [Abstract][Full Text] [Related]
50. The Bewildering Antitubercular Action of Pyrazinamide. Lamont EA; Dillon NA; Baughn AD Microbiol Mol Biol Rev; 2020 May; 84(2):. PubMed ID: 32132245 [TBL] [Abstract][Full Text] [Related]
51. Pancreatic mass caused by Mycobacterium tuberculosis with reduced drug sensitivity. Small G; Wilks D J Infect; 2001 Apr; 42(3):201-2. PubMed ID: 11545552 [TBL] [Abstract][Full Text] [Related]
52. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Kwon YS; Jeong BH; Koh WJ Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169 [TBL] [Abstract][Full Text] [Related]
53. Recommendations for treating children with drug-resistant tuberculosis. Galli L; Lancella L; Garazzino S; Tadolini M; Matteelli A; Migliori GB; Principi N; Villani A; Esposito S; Pharmacol Res; 2016 Mar; 105():176-82. PubMed ID: 26821118 [TBL] [Abstract][Full Text] [Related]
54. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis. Patel RV; Riyaz SD; Park SW Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806 [TBL] [Abstract][Full Text] [Related]
55. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Dharmadhikari AS; Mphahlele M; Venter K; Stoltz A; Mathebula R; Masotla T; van der Walt M; Pagano M; Jensen P; Nardell E Int J Tuberc Lung Dis; 2014 Sep; 18(9):1019-25. PubMed ID: 25189547 [TBL] [Abstract][Full Text] [Related]
56. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis. Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687 [TBL] [Abstract][Full Text] [Related]
57. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Matteelli A; Carvalho AC; Dooley KE; Kritski A Future Microbiol; 2010 Jun; 5(6):849-58. PubMed ID: 20521931 [TBL] [Abstract][Full Text] [Related]
58. Increasing drug resistance of Mycobacterium tuberculosis in a medical center---what about in Taiwan overall? Chiang CY; Kim SJ J Formos Med Assoc; 2009 Jan; 108(1):1-3. PubMed ID: 19181601 [No Abstract] [Full Text] [Related]
59. Infectious disease. Drug-resistant TB on the rise. Stokstad E Science; 2000 Mar; 287(5462):2391. PubMed ID: 10766610 [No Abstract] [Full Text] [Related]
60. Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK. Melzer M; Gupta N; Petersen I; Cook S; Hall B Int J Infect Dis; 2010 Aug; 14(8):e717-22. PubMed ID: 20542460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]